Head to Head Survey: Werewolf Therapeutics (HOWL) and The Competition

Werewolf Therapeutics (NASDAQ:HOWLGet Rating) is one of 937 publicly-traded companies in the “Pharmaceutical preparations” industry, but how does it weigh in compared to its rivals? We will compare Werewolf Therapeutics to related companies based on the strength of its valuation, earnings, risk, dividends, institutional ownership, analyst recommendations and profitability.


This table compares Werewolf Therapeutics and its rivals’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Werewolf Therapeutics N/A -57.14% -31.36%
Werewolf Therapeutics Competitors -4,343.49% -115.17% -11.41%

Earnings and Valuation

This table compares Werewolf Therapeutics and its rivals top-line revenue, earnings per share and valuation.

Gross Revenue Net Income Price/Earnings Ratio
Werewolf Therapeutics N/A -$49.98 million -0.05
Werewolf Therapeutics Competitors $1.83 billion $238.78 million -1.59

Werewolf Therapeutics’ rivals have higher revenue and earnings than Werewolf Therapeutics. Werewolf Therapeutics is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.

Analyst Recommendations

This is a breakdown of recent recommendations and price targets for Werewolf Therapeutics and its rivals, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Werewolf Therapeutics 0 0 5 0 3.00
Werewolf Therapeutics Competitors 6042 20549 42936 854 2.55

Werewolf Therapeutics presently has a consensus target price of $26.20, indicating a potential upside of 498.17%. As a group, “Pharmaceutical preparations” companies have a potential upside of 96.54%. Given Werewolf Therapeutics’ stronger consensus rating and higher probable upside, analysts clearly believe Werewolf Therapeutics is more favorable than its rivals.

Institutional and Insider Ownership

69.1% of Werewolf Therapeutics shares are held by institutional investors. Comparatively, 45.5% of shares of all “Pharmaceutical preparations” companies are held by institutional investors. 14.4% of shares of all “Pharmaceutical preparations” companies are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.


Werewolf Therapeutics beats its rivals on 7 of the 12 factors compared.

About Werewolf Therapeutics (Get Rating)

Werewolf Therapeutics, Inc., a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. The company, through its proprietary PREDATOR platform, designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies. Its lead product candidates are WTX-124, a conditionally activated Interleukin-2 INDUKINE molecule for the treatment of advanced solid tumors; and WTX-330, a conditionally activated Interleukin-12 INDUKINE molecule for the treatment of relapsed or refractory advanced or metastatic solid tumors or lymphoma. The company is also developing WTX-613, a conditionally activated interferon alpha INDUKINE molecule for the treatment of solid tumors and hematologic malignancies. Werewolf Therapeutics, Inc. was incorporated in 2017 and is headquartered in Cambridge, Massachusetts.

Receive News & Ratings for Werewolf Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Werewolf Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.